���重受体激动剂的分子设计 — Worked Examples

By Editorial Desk · published 2026-06-25 · last reviewed 2026-08-01 · News

phase 2 trial raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Peptide Identity and Receptor Targets

Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.

Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.

Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.

Retatrutide at a glance

Handling and Analytical Methods

Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.

Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.

Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.

Related pages on this site

• Material briefing
• Portable checklist
• Optimized primer
• Clear overview
• Scheduled report
• Durable dataset
• Portable guide
• Measured handbook

Retatrutide Background and Receptor Activity

The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.

Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.

Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.

Supporting material

=== Circadian rhythm sleep disorders === Melatonin may be useful in the treatment of delayed sleep phase syndrome. Melatonin is known to reduce jet lag, especially in eastward travel. However, if it is not taken at the correct time, it can instead delay adaptation. Melatonin appears to have limited use against the sleep problems of people who work shift work. Tentative evidence suggests that it increases the length of time people are able to sleep. Meta-analyses, published between 2005 and 2017, appear to show different results as to whether melatonin is effective for circadian rhythm sleep disorders or not. Some found that it was effective, while others found no evidence of effectiveness. Meta-analyses of melatonin for delayed sleep phase syndrome that found it effective have reported that it improves time to sleep onset by about 40 minutes (0.67 hours) and advances onset of endogenous melatonin secretion by about 1.2 hours (72 minutes). One meta-analysis found that melatonin was notably more effective in improving sleep onset latency in people with delayed sleep phase syndrome than in people with insomnia (improvement of 39 minutes vs. 7 minutes, respectively). One meta-analysis found that melatonin was probably effective for jet lag syndrome.

=== Phase 1 === KH-001 (KH001) – atypical selective serotonin reuptake inhibitor (SSRI), phosphodiesterase (PDE) inhibitor (purified Sceletium tortuosum (kanna) alkaloid; possibly mesembrine) – premature ejaculation [32] VV-913 (VV913) – undefined mechanism of action – premature ejaculation [33]

Turner was a senior lecturer at the University of Auckland from 2005 until becoming an associate professor in 2013. On 1 January 2014, she was appointed as a professor in the Department of General Practice and Primary Care at the same university. Turner has been part of the General Practice team at Newtown Union Health Services (NUHS), Broadway, Wellington, since 2011, and is an associate and spokesperson for the Child Poverty Action Group.

=== Crumpled graphene === In 2016, Brown University introduced a method for "crumpling" graphene, adding wrinkles to the material on a nanoscale. This was achieved by depositing layers of graphene oxide onto a shrink film, then shrunken, with the film dissolved before being shrunken again on another sheet of film. The crumpled graphene became superhydrophobic, and when used as a battery electrode, the material was shown to have as much as a 400% increase in electrochemical current density.

Sources: en.wikipedia.org

Notes from published material

== Co-translational versus post-translational translocation == In both prokaryotes and eukaryotes signal sequences may act co-translationally or post-translationally. The co-translational pathway is initiated when the signal peptide emerges from the ribosome and is recognized by the signal-recognition particle (SRP). SRP then halts further translation (translational arrest only occurs in Eukaryotes) and directs the signal sequence-ribosome-mRNA complex to the SRP receptor, which is present on the surface of either the plasma membrane (in prokaryotes) or the ER (in eukaryotes). Once membrane-targeting is completed, the signal sequence is inserted into the translocon. Ribosomes are then physically docked onto the cytoplasmic face of the translocon and protein synthesis resumes. The post-translational pathway is initiated after protein synthesis is completed. In prokaryotes, the signal sequence of post-translational substrates is recognized by the SecB chaperone protein that transfers the protein to the SecA ATPase, which in turn pumps the protein through the translocon. Although post-translational translocation is known to occur in eukaryotes, it is poorly understood. It is known that in yeast post-translational translocation requires the translocon and two additional membrane-bound proteins, Sec62 and Sec63.

=== Interest during COVID-19 pandemic === Sertraline has been the most sought-after antidepressant worldwide before, during, and after the COVID-19 pandemic, according to Google Trends data. The pandemic has led to an increase in searches for antidepressants, with sertraline, fluoxetine, duloxetine, and venlafaxine showing the highest search volumes, whereas searches of citalopram decreased during the pandemic.

== Production Sites == IMA Life has four production sites, one located in the outskirts of Bologna, one in Calenzano near Florence, one in Tonawanda, NY (USA) and one in Beijing (China). Apart from its manufacturing plants, it has sales and service centers at Puerto Rico, Brazil, France, Italy, Ireland, China and Japan.

Sources: en.wikipedia.org

Further detail

The lower the barrier and the masses of the fragments, the greater the probability per unit time of a split. Protons in a nucleus are bound together by the strong force, which counterbalances the Coulomb repulsion between positively charged protons. In heavier nuclei, larger numbers of uncharged neutrons are needed to reduce repulsion and confer additional stability. Even so, as physicists started to synthesize elements that are not found in nature, they found the stability decreased as the nuclei became heavier. Thus, they speculated that the periodic table might come to an end. The discoverers of plutonium (element 94) considered naming it "ultimium", thinking it was the last. Following the discoveries of heavier elements, of which some decayed in microseconds, it then seemed that instability with respect to spontaneous fission would limit the existence of heavier elements. In 1939, an upper limit of potential element synthesis was estimated around element 104, and following the first discoveries of transactinide elements in the early 1960s, this upper limit prediction was extended to element 108.

Though there is no strict rule on what to consume and what not to, the food habits of Hindus vary according to their specific caste and sub-caste, community, location, custom and varying traditions. Historically and currently, a majority of Hindus (about 70%) eat meat, while a large proportion of Hindus are vegetarian (about 30%). Some sects of Hinduism such as Vaishnavism follow the purest form of vegetarianism as an ideal while Shaktism and Tantric sects freely consume chicken, mutton (goat and sheep meat), fish and eggs. The reasons stated by Jains and Vaishnavas are: the principle of nonviolence (ahimsa) applied to animals; the intention to offer only "pure" (vegetarian) food to a deity and then to receive it back as prasada; and the conviction that a sattvic diet is beneficial for a healthy body. A sattvic diet is lacto-vegetarian, which includes dairy, but excludes eggs. An overwhelming majority of the Hindus consider the cow to be a holy and sacred animal whose slaughter for meat is forbidden. Thus, beef is a taboo for the majority of Hindus, Jains and Sikhs

The redox reactions catalyzed by oxidoreductases are vital in all parts of metabolism, but one particularly important area where these reactions occur is in the release of energy from nutrients. Here, reduced compounds such as glucose and fatty acids are oxidized, thereby releasing energy. This energy is transferred to NAD+ by reduction to NADH, as part of beta oxidation, glycolysis, and the citric acid cycle. In eukaryotes the electrons carried by the NADH that is produced in the cytoplasm are transferred into the mitochondrion (to reduce mitochondrial NAD+) by mitochondrial shuttles, such as the malate-aspartate shuttle. The mitochondrial NADH is then oxidized in turn by the electron transport chain, which pumps protons across a membrane and generates ATP through oxidative phosphorylation. These shuttle systems also have the same transport function in chloroplasts. Since both the oxidized and reduced forms of nicotinamide adenine dinucleotide are used in these linked sets of reactions, the cell maintains significant concentrations of both NAD+ and NADH, with the high NAD+/NADH ratio allowing this coenzyme to act as both an oxidizing and a reducing agent. In contrast, the main function of NADPH is as a reducing agent in anabolism, with this coenzyme being involved in pathways such as fatty acid synthesis and photosynthesis. Since NADPH is needed to drive redox reactions as a strong reducing agent, the NADP+/NADPH ratio is kept very low. Although it is important in catabolism, NADH is also used in anabolic reactions, such as gluconeogenesis.

==== Methodological issues in studies ==== Knowledge about the pharmacokinetics of oral progesterone has been complicated by the use of flawed analytical techniques. When progesterone is taken orally, due to first-pass metabolism, very high levels of its metabolites occur. Most previous studies have used a method known as immunoassay (IA) to measure progesterone levels. However, IA without chromatographic separation (CS) has high cross-reactivity and is unable to differentiate between progesterone and metabolites such as allopregnanolone and pregnanolone. As a result, studies that have assessed the pharmacokinetics of oral progesterone using IA have reported falsely high progesterone levels and inaccurate dependent pharmacokinetic parameters. Comparative studies using reliable and exact methods such as liquid chromatography–mass spectrometry (LC–MS) and IA in conjunction with adequate CS have found that IA without CS overestimates levels of progesterone by 5- to 8-fold. For this reason, the use of reliable assays is mandatory when studying the pharmacokinetics of oral progesterone, and an awareness of these methodological issues is likewise essential for an accurate understanding of the pharmacokinetics of oral progesterone. Conversely, the same issues are not applicable to parenteral routes of progesterone such as vaginal administration and intramuscular injection, because these routes are not subject to a first pass and relatively low levels of progesterone metabolites are formed.

Sources: en.wikipedia.org

Frequently asked questions